Avesthagen Pharma AG (APAG) has announced an agreement with Elpen Pharmaceutical Co Inc, a leader in life-sciences for the distribution of Avdesp, a biosimilar product in seven EU and six non-EU territories.
Avdesp, a biosimilar for Darbepoetin alfa Aranesp will be used for the treatment of anaemia resulting from chronic kidney disorders and cancer chemotherapy.
"We are excited about this alliance as we start our marketing in some most interesting countries, it will give us an opportunity to know these markets and interact with its people," said Dr Villoo Morawala-Patell, chairperson, APAG.
The current global sales for the product are over $2.5 billion, and APAG hopes to price Avdesp to come within the reach of a wider global community.
"The company is committed to deliver affordable healthcare for humanity," added Dr Patell.
APAG is currently engaged with other opportunities for its 'biosimilars' and 'biobetters' in several countries.
APAG is working with different outsourcing organizations so that the product comes to the market at the earliest. APAG has identified Syngene International Ltd for fill and finish; Kemwell Biopharma as a CMO (contract manufacturing organization); and PRA International, a global CRO to conduct and carry out the Phase I clinical trial in Netherlands followed by Phase III in India.
Anda sedang membaca artikel tentang
Avesthagen ties up with Elpen for biosimilar product
Dengan url
http://cegahkeropostulang.blogspot.com/2013/11/avesthagen-ties-up-with-elpen-for.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Avesthagen ties up with Elpen for biosimilar product
namun jangan lupa untuk meletakkan link
Avesthagen ties up with Elpen for biosimilar product
sebagai sumbernya
0 komentar:
Posting Komentar